24 results
8-K
EX-99.2
AXLA
Axcella Health Inc.
29 Sep 22
Regulation FD Disclosure
9:15am
cycle AA Metabolism AXA1125 AXA1125 GLP - 1 SCD1 FGF21 THR - β PPAR FXR Single Targets Single Targets Single Targets TGF β Cyclophilin CCR2/5 … across NASH Disease Drivers Fibrosis Inflammation Metabolism AXA1125 AXA1125 AXA1125 GLP - 1 SCD1 FGF21 THR - β PPAR FXR Single Targets Single Targets
S-1/A
EX-10.4
AXLA
Axcella Health Inc.
30 Apr 19
IPO registration (amended)
6:06am
objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals, (ii) bonus … a determination with respect to the attainment of the performance targets relating to the Corporate Performance Goals. Notwithstanding the foregoing
8-K
EX-99.2
AXLA
Axcella Health Inc.
6 May 21
Axcella Reports First Quarter Financial Results and Provides Business Update
7:51am
metabolic pathways; potential for multifactorial activity in cirrhosis Poor Ammonia Handling Disease Factors Targets/Pathways EMMsGoals AXA1665 … therapies approved in U.S. Comorbid population (T2D, heart disease, etc.) that already is on ~7 medications1 Most drug candidates have single targets
8-K
EX-99.1
AXLA
Axcella Health Inc.
10 Jan 22
Other Events
8:00am
single targets, leading to combination therapy development – Administration, safety tolerability challenges (injectables, lipids, pruritis, DDI, etc … sensitivity Hepatocyte ballooning Fibrogenesis & hepatic stellate cell activation Gut barrier/ tight junction Disease Factors Targets/Pathways
8-K
EX-99.2
AXLA
Axcella Health Inc.
2 Aug 22
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
4:06pm
and data to study its potential in Long Covid
© 2022 Axcella Therapeutics. All rights reserved. 35 AXA1125 Targets Key Environment, Inflammation
424B4
xc7v1z10goh7
9 May 19
Prospectus supplement with pricing info
4:29pm
DRS/A
n2daenog 64nhpri
15 Mar 19
Draft registration statement (amended)
12:00am
S-1/A
x6ejlv3 5k4un0
30 Apr 19
IPO registration (amended)
6:06am
DRS
c81l7qd09b a1wrp729
28 Jan 19
Draft registration statement
12:00am
S-1
ygv0gtetprv2h
12 Apr 19
IPO registration
7:02am
10-K
qbe33 8nmkkjrkusgt
23 Mar 20
Annual report
4:12pm